Deals this week: NicOx, FibroGen, Omeros


NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total.

Based in France, NicOx is a pharmaceutical company focused on the development of treatments for ophthalmic conditions. The company plans to use the funds to progress the development of its products and for general corporate purposes.

US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total.

The company plans to use the funds towards product development, clinical programmes and commercialisation activities.

"US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total."

Omeros has announced a public offering of three million common stock shares priced at $22.75 a share to raise $68.25m.

The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.

Apellis Pharmaceuticals has raised $60m in a Series E funding round led by Sectoral Asset Management.

Based in the US, the clinical-stage biopharmaceutical company plans to use the funds to progress the development of its APL-2 drug.